Business Wire

LabVantage Solutions and The Netherlands Forensic Institute (NFI) Partner to Advance Digital Transformation in Forensic Science

4.12.2024 13:30:00 CET | Business Wire | Press release

Share

—New Collaboration Enhances NFI’s IT Infrastructure with Advanced LIMS to Streamline Workflows, Improve Data Integrity, and Optimize Forensic Operations—

LabVantage Solutions, Inc., the leading provider of laboratory informatics solutions and services, including purpose-built LIMS platforms enabling rapid deployment at reduced costs, and The Netherlands Forensic Institute (NFI) today jointly announced a partnership to digitalize forensic laboratory workflows as part of NFI’s IT renewal initiative. A key aspect of this collaboration is the implementation of LabVantage Solutions’ Laboratory Information Management System (LIMS), which is designed to streamline NFI’s forensic operations by replacing fragmented processes and incorporating advanced capabilities.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241204274659/en/

null

(Graphic: Business Wire)

NFI’s IT renewal initiative aims to modernize its infrastructure by replacing outdated manual systems with streamlined, automated workflows. Currently, the workflows involve multiple manual registrations across different systems, which can lead to time-consuming tasks and potential inconsistencies. The integration of LabVantage LIMS will unify data entry and enhance traceability, ensuring that data is efficiently recorded and utilized. It will also improve overall clarity and operational efficiency across forensic investigations, saving valuable time for all involved.

Peter Blom, Chief Information Officer of NFI, expressed his enthusiasm for the project: “This partnership marks a significant milestone in our journey to innovate and improve our forensic services. By integrating a sophisticated LIMS, we are setting a new standard in forensic science.”

“We are proud to work alongside NFI in their mission to enhance forensic operations,” said Michel Gerlicher, President, LabVantage International. “This collaboration will bring about a new era of efficiency and reliability in their laboratory workflows.”

The project includes contributions from Protinus, which served as the IT broker, and Capgemini, which is developing the sovereign cloud infrastructure to host the LIMS. The new system will integrate seamlessly into NFI’s operations, ensuring compliance with stringent security standards while enabling forensic experts to work faster and more confidently. By leveraging a secure, sovereign cloud infrastructure, the partnership will meet the highest standards of data protection and regulatory compliance, including BIO (Baseline Information Security for Government) and BBN (Baseline Information Security for Enterprises) requirements.

Alan Marcus, Chief Growth Officer at LabVantage Solutions, emphasized the broader implications of this alliance: “We are excited to see the real-life impact our investments in industry-specific solutions bring to our clients. With Software-as-a-Service (SaaS) becoming the de facto delivery standard, we expect vertical solutions to prove increasingly impactful, allowing clients to benefit from the latest innovations without being held back by past adaptations required by industry-agnostic software. NFI’s validation that our forensics solutions are fit for purpose is encouraging, and we are humbled to contribute to the fact-finding mission of NFI’s world-leading forensic laboratories.”

LabVantage Solutions, in joint effort with Protinus and Capgemini, will ensure the new system is secure and fully compliant with all required standards. By implementing LabVantage LIMS, NFI will streamline processes, enhance data accuracy, and improve data management, reinforcing its commitment to innovation and reliability. This partnership strengthens NFI’s role as a leader in delivering reliable forensic services to organizations around the world, while further establishing LabVantage Solutions’ prominence in the enterprise laboratory software solutions industry.

To learn more about LabVantage Solutions’ end-to-end informatics solutions for the complete forensic life cycle, please visit labvantage.com or contact us here.

About LabVantage Solutions
A recognized leader in enterprise laboratory software solutions, LabVantage Solutions dedicates itself to improving customer outcomes by transforming data into knowledge. Its highly configurable, 100% browser-based platform consists of LIMS, ELN, LES, SDMS, and advanced analytics, supporting seamless deployment into any environment. Serving over 1,500 customers across life sciences, pharmaceuticals, biobanking, food & beverage, forensics, and more, LabVantage Solutions empowers innovation, helps improve product quality, and ensures compliance with industry regulations. Headquartered in Somerset, NJ, with offices worldwide, LabVantage Solutions has driven laboratory digital transformation for over 40 years. For more information, visit labvantage.com.

About The Netherlands Forensic Institute (NFI):
The Netherlands Forensic Institute is dedicated to providing high-quality forensic services to support justice, peace, and security. The NFI has achieved this position by constantly improving its products and services. Science and innovation at the NFI are strongly driven by experiences from forensic practice. Through this innovative approach and commitment to excellence, the NFI serves both national and international clients, offering a wide range of forensic products and services. For more information, visit https://www.forensischinstituut.nl/.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241204274659/en/

null

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

U.S. FDA Grants Priority Review to BeOne Medicines’ TEVIMBRA in First-Line HER2+ GEA29.4.2026 12:00:00 CEST | Press release

TEVIMBRA plus ZIIHERA and chemotherapy regimen delivered statistically significant median OS of 26.4 months, an unprecedented result in this challenging diseaseResults from the global Phase 3 HERIZON-GEA-01 study demonstrate potential to change clinical practice in advanced HER2+ gastroesophageal adenocarcinoma BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to a supplemental Biologics License Application (sBLA) for TEVIMBRA® (tislelizumab) in combination with ZIIHERA® (zanidatamab) and chemotherapy for the first-line treatment of unresectable locally advanced/metastatic HER2-positive (HER2) gastric, gastroesophageal junction, or esophageal adenocarcinoma. The FDA has also granted Breakthrough Therapy Designation to the regimen of ZIIHERA in combination with fluoropyrimidine- and platinum-containing chemotherapy, with and without TEVIMBRA, in this indica

European Commission (EC) Approves Henlius and Organon’s POHERDY® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe29.4.2026 11:30:00 CEST | Press release

Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the European Commission (EC) has granted marketing authorization for POHERDY® (pertuzumab) 420 mg/14 mL injection for intravenous use, the first and only approved biosimilar to PERJETA (pertuzumab) in Europe, for all indications of the reference product.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429686426/en/ “As the first, and currently the only, pertuzumab biosimilar in Europe, the EC’s approval of POHERDY marks an important milestone in expanding access to treatments for patients with certain HER2-positive breast cancers, particularly as breast cancer is the most commonly diagnosed cancer among women in the European Union,” said Joe Azzinaro, Vice President, Global Commercial Lead Biosimilars, at Organon.2,3 “Organon’s growing global portfolio of biosimilars reinforces our ongoing commitment to supporting the sustainability of healt

Andreas Goppelt Appointed Managing Director of OrphaCare29.4.2026 10:27:00 CEST | Press release

OrphaCare, a global specialist for the development and marketing of medical devices for drug delivery and part of the AOP Health Group, has appointed Andreas Goppelt as its new Managing Director, succeeding Georg Fischer. In this role, the seasoned medical device expert will focus on broadening the company’s strategic scope and driving its next phase of growth. OrphaCare plays a key role in supporting AOP Health’s integrated therapies approach, and the Group’s long-term expansion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429303533/en/ Portrait Andreas Goppelt, Managing Director OrphaCare (copyright: AOP Health/Studio Koekart) Andreas Goppelt brings more than 25 years of leadership experience across MedTech, biotechnology and the pharmaceutical industry. He has a proven track record of driving innovation, scaling global organizations, and delivering growth in highly regulated healthcare environments. In his new role,

The Jury Has Been Announced for the Third Edition of the Reply AI Film Festival, Dedicated to the Best Short Films Generated With Artificial Intelligence29.4.2026 10:00:00 CEST | Press release

Gabriele Salvatores, together with Rob Minkoff, Catherine Hardwicke, Jed Weintrob, Christina Lee Storm, Nils Hartmann, Guillem Martinez Roura, Filippo Rizzante, Giacomo Mineo, Brian Welk and Denise Negri, will judge the short films in competition based on creativity, production quality and the use of Artificial Intelligence. Reply [EXM, STAR: REY], an international group specialized in creating new business models enabled by AI and long committed to guiding younger generations in exploring emerging technologies, presents the jury of the third edition of the Reply AI Film Festival, the international competition aimed at creatives, directors, and filmmakers who want to challenge themselves in producing short films created using Artificial Intelligence tools. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429288361/en/ “Imaginatio Nova” is the theme of the 2026 edition, an invitation to explore a new phase of imagination, wh

Bregal Milestone Announces Majority Growth Investment in CoreGo, a Leading European Open-Loop Payment and Event Technology Company29.4.2026 10:00:00 CEST | Press release

Investment follows over 98% annual growth and supports CoreGo’s continued market expansion Bregal Milestone, a leading European software growth private equity firm, today announced a majority strategic growth investment in CoreGo Oy ("CoreGo" or the "Company"), a leading provider of open-loop payments and integrated technology solutions for festivals, sports events, and venues across Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427991105/en/ Founded in Helsinki in 2015 by Hannu Elomaa and CTO Nikoteemu Väänänen, CoreGo has built one of Europe's most differentiated open-loop payment infrastructure and event technology businesses. Serving approximately 250 customers across the Nordics and DACH region, the Company delivers an integrated showtime-critical suite of solutions through CoreGo Cloud, unifying payments, access, networks, and data into a single real-time operating system. CoreGo’s in-house private network

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye